{"id":69410,"date":"2026-07-06T11:29:33","date_gmt":"2026-07-06T03:29:33","guid":{"rendered":"https:\/\/flcube.com\/?p=69410"},"modified":"2026-07-06T11:29:34","modified_gmt":"2026-07-06T03:29:34","slug":"chinas-nmpa-unveils-comprehensive-regulatory-framework-for-cell-and-gene-therapy-products-with-streamlined-review-pathways","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69410","title":{"rendered":"China&#8217;s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has issued two landmark regulatory guidelines\u2014the <strong>Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition)<\/strong> and the <strong>Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)<\/strong>\u2014alongside a draft announcement proposing significant <strong>optimizations to the review and approval process<\/strong> for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.<\/p>\n\n\n\n<h2 id=\"h-regulatory-framework-overview\" class=\"wp-block-heading\">Regulatory Framework Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Document<\/th><th>Key Purpose<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Cell Therapy Guideline (2026)<\/strong><\/td><td>Defines scope, classification, and exclusions for CTMPs<\/td><td>Effective immediately<\/td><\/tr><tr><td><strong>Gene Therapy Guideline (2026)<\/strong><\/td><td>Establishes clear parameters for GTMP definition and categorization<\/td><td>Effective immediately<\/td><\/tr><tr><td><strong>CGT Review Optimization Announcement<\/strong><\/td><td>Proposes expedited pathways and support mechanisms for CGT development<\/td><td>Draft for public comment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-cell-therapy-medicinal-products-ctmps-definition-amp-classification\" class=\"wp-block-heading\">Cell Therapy Medicinal Products (CTMPs) \u2013 Definition &amp; Classification<\/h2>\n\n\n\n<h3 id=\"h-core-definition\" class=\"wp-block-heading\">Core Definition<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">CTMPs are defined as drugs that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Use human cells, tissues, or body fluids as starting raw materials<\/li>\n\n\n\n<li>Are manufactured through ex vivo manipulation<\/li>\n\n\n\n<li>Have cells as the active ingredient<\/li>\n\n\n\n<li>Achieve intended use through mechanisms including:<\/li>\n\n\n\n<li>Regulating biological activity, immunological properties, or metabolic status of cells<\/li>\n\n\n\n<li>In vivo cell replacement, regeneration, and functional reconstruction<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-classification-system\" class=\"wp-block-heading\">Classification System<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-genetically modified CTMPs<\/strong>: No genetic material alteration during ex vivo manipulation<\/li>\n\n\n\n<li><strong>Ex vivo genetically modified CTMPs<\/strong>: Genetic modification occurs during manufacturing process<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-explicit-exclusions\" class=\"wp-block-heading\">Explicit Exclusions<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Blood components for transfusion derived from blood collection<\/li>\n\n\n\n<li>Unprocessed human cells, tissues, or organs for transplantation<\/li>\n\n\n\n<li>Artificial embryos and germ cells used in reproductive technologies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-gene-therapy-medicinal-products-gtmps-definition-amp-classification\" class=\"wp-block-heading\">Gene Therapy Medicinal Products (GTMPs) \u2013 Definition &amp; Classification<\/h2>\n\n\n\n<h3 id=\"h-core-definition-0\" class=\"wp-block-heading\">Core Definition<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">GTMPs are defined as drugs that achieve intended use by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Introducing exogenous gene sequences via nucleic acids (DNA\/RNA)<\/li>\n\n\n\n<li>Using viral or non-viral vectors for delivery<\/li>\n\n\n\n<li>Employing nucleases\/proteases acting on specific genes<\/li>\n\n\n\n<li>Specifically altering gene sequences or regulating gene expression through:<\/li>\n\n\n\n<li>Replacement, compensation, blockade, correction, or silencing of specific genes<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-classification-system-0\" class=\"wp-block-heading\">Classification System<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-microbial vector-based GTMPs<\/strong>: Utilize non-viral delivery systems<\/li>\n\n\n\n<li><strong>Microbial vector-based GTMPs<\/strong>: Employ viral or other microbial vectors<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-explicit-exclusions-0\" class=\"wp-block-heading\">Explicit Exclusions<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Prophylactic vaccines<\/li>\n\n\n\n<li>Chemically synthesized oligonucleotide drugs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-review-amp-approval-optimization-measures\" class=\"wp-block-heading\">Review &amp; Approval Optimization Measures<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Initiative<\/th><th>Benefit<\/th><th>Timeline\/Details<\/th><\/tr><\/thead><tbody><tr><td><strong>30-Day Clinical Trial Channel<\/strong><\/td><td>Expedited IND review for eligible CGT products<\/td><td>30-day review timeline vs. standard<\/td><\/tr><tr><td><strong>Full-Process Guidance Services<\/strong><\/td><td>Enhanced CDE support for high-value CGT candidates<\/td><td>Type I meeting communication, pre-receiving assistance<\/td><\/tr><tr><td><strong>Priority Review &amp; Approval<\/strong><\/td><td>Accelerated marketing application review<\/td><td>For products with new targets, mechanisms, or significant clinical value<\/td><\/tr><tr><td><strong>Manufacturing Process Change Review<\/strong><\/td><td>Faster approval for post-marketing manufacturing upgrades<\/td><td><strong>130 working days<\/strong> (reduced from 200 working days)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-focus-areas-for-cgt-development\" class=\"wp-block-heading\">Strategic Focus Areas for CGT Development<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA explicitly encourages R&amp;D investment in:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Malignant tumors<\/strong><\/li>\n\n\n\n<li><strong>Rare diseases<\/strong><\/li>\n\n\n\n<li><strong>Genetic disorders<\/strong><\/li>\n\n\n\n<li><strong>Immune system diseases<\/strong><\/li>\n\n\n\n<li><strong>Neurodegenerative diseases<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Additional incentives include support for <strong>global simultaneous R&amp;D<\/strong> and <strong>international multi-center clinical trials<\/strong> conducted in China.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-industry-implications\" class=\"wp-block-heading\">Market Impact &amp; Industry Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Clarity:<\/strong> The guidelines eliminate previous ambiguities around CGT product definitions, providing clear boundaries for developers<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Chinese CGT companies gain predictable regulatory pathways comparable to FDA and EMA frameworks<\/li>\n\n\n\n<li><strong>Investment Attraction:<\/strong> Streamlined review timelines and priority programs make China an attractive jurisdiction for global CGT development<\/li>\n\n\n\n<li><strong>Innovation Catalyst:<\/strong> The 30-day clinical trial channel could accelerate first-in-human studies by 60-70% compared to standard timelines<\/li>\n\n\n\n<li><strong>Manufacturing Flexibility:<\/strong> Reduced review time for process changes addresses a key industry pain point in CGT commercial-scale manufacturing<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The comprehensive regulatory package positions China as a leading destination for cell and gene therapy innovation, with clear definitions, accelerated pathways, and targeted support for high-impact therapeutic areas.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines\u2014the Guideline on the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"class_list":["post-69410","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines\u2014the Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition) and the Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)\u2014alongside a draft announcement proposing significant optimizations to the review and approval process for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69410\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines\u2014the Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition) and the Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)\u2014alongside a draft announcement proposing significant optimizations to the review and approval process for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69410\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T03:29:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-06T03:29:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69410#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69410\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways\",\"datePublished\":\"2026-07-06T03:29:33+00:00\",\"dateModified\":\"2026-07-06T03:29:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69410\"},\"wordCount\":583,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69410#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69410\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69410\",\"name\":\"China's NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-06T03:29:33+00:00\",\"dateModified\":\"2026-07-06T03:29:34+00:00\",\"description\":\"China's National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines\u2014the Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition) and the Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)\u2014alongside a draft announcement proposing significant optimizations to the review and approval process for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69410#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69410\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69410#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines\u2014the Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition) and the Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)\u2014alongside a draft announcement proposing significant optimizations to the review and approval process for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69410","og_locale":"en_US","og_type":"article","og_title":"China's NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways","og_description":"China's National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines\u2014the Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition) and the Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)\u2014alongside a draft announcement proposing significant optimizations to the review and approval process for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.","og_url":"https:\/\/flcube.com\/?p=69410","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-06T03:29:33+00:00","article_modified_time":"2026-07-06T03:29:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69410#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69410"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways","datePublished":"2026-07-06T03:29:33+00:00","dateModified":"2026-07-06T03:29:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69410"},"wordCount":583,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69410#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69410","url":"https:\/\/flcube.com\/?p=69410","name":"China's NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-06T03:29:33+00:00","dateModified":"2026-07-06T03:29:34+00:00","description":"China's National Medical Products Administration (NMPA) has issued two landmark regulatory guidelines\u2014the Guideline on the Scope and Classification of Cell Therapy Medicinal Products (2026 Edition) and the Guideline on the Scope and Classification of Gene Therapy Medicinal Products (2026 Edition)\u2014alongside a draft announcement proposing significant optimizations to the review and approval process for cell and gene therapy (CGT) drugs. The comprehensive framework aims to standardize CGT classification while accelerating innovation in this rapidly evolving therapeutic area.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69410#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69410"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69410#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69410"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69410\/revisions"}],"predecessor-version":[{"id":69412,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69410\/revisions\/69412"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}